ACTON, Mass. — Insulet Corporation said it will make its debut at CES 2026, outlining a vision it calls “liveable technology” as it showcases how human-centered design and intelligent automation can reshape connected health for people living with diabetes.
The company plans to highlight its approach through an immersive booth experience, a digital health track panel discussion, and media demonstrations focused on reducing the daily mental burden of chronic disease management. Insulet said the presentations will center on how tubeless, automated insulin delivery can improve health outcomes while fitting more naturally into everyday life.
Liveable technology, according to the company, reflects a philosophy of building connected health systems that are intuitive, adaptive, and largely operate in the background. As digital health tools become more prevalent, Insulet said people increasingly want technology that surfaces insights only when they matter and otherwise minimizes cognitive load.
“CES is where the future of technology takes shape, and Insulet is proud to help bring the voice of those living with diabetes into that future,” said Manoj Raghunandanan, Chief Growth Officer at Insulet. “Each day brings dozens of choices that can be tiring and complex for anyone managing diabetes. Our goal is to ease that burden by creating technology that fits naturally into life. Omnipod reflects that vision of liveable technology, progress that helps people feel supported and more in control. By innovating at the nexus of MedTech, healthcare, and consumer, we’re showing that real change happens when life and technology actually work together.”
Throughout CES 2026, Insulet will demonstrate how its Omnipod 5 tubeless automated insulin delivery system supports people with type 1 and insulin-intensive type 2 diabetes by managing blood glucose levels through automation that works seamlessly in the background. The company said the system is designed to reduce the time and mental effort required for diabetes management while helping users stay within safe glucose ranges.
